NCT lookup

Inclusion Criteria:

* An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the subject
* Subject is male or female at least 18 years of age
* Female subject must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception
* Documented diagnosis of adult-onset Psoriatic Arthritis (PsA) meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 6 months prior to Screening with active PsA and must have at Baseline tender joint count (TJC) \>=3 out of 68 and swollen joint count (SJC) \>=3 out of 66
* Subject must be negative for rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies
* Subject must have at least 1 active psoriatic lesion(s) and/or a documented history of psoriasis (PSO)
* Subject must be a suitable candidate for treatment with adalimumab and has no contraindications to receive adalimumab as per the local label as assessed by the Investigator
* Subjects currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics (including mild opioids), corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

Exclusion Criteria:

* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study
* Subjects with current or prior exposure to any biologics for the treatment of Psoriatic Arthritis (PsA) or Psoriasis (PSO)
* Subject has an active infection or a history of recent serious infections
* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
* Subject has a diagnosis of inflammatory conditions other than PSO or PsA. Subjects with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease at Screening or Baseline
* Subject had acute anterior uveitis within 6 weeks of Baseline
* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
* Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and guttate PSO, or drug-induced PSO)
* Presence of active suicidal ideation, or moderately severe major depression or severe major depression
* Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

• Phoenix, Arizona, United States
• San Diego, California, United States
• Tustin, California, United States
• Palm Harbor, Florida, United States
• Tampa, Florida, United States
• Atlanta, Georgia, United States
• Lexington, Kentucky, United States
• Hagerstown, Maryland, United States
• St Louis, Missouri, United States
• Albuquerque, New Mexico, United States
• Brooklyn, New York, United States
• Charlotte, North Carolina, United States
• Dayton, Ohio, United States
• Duncansville, Pennsylvania, United States
• Wyomissing, Pennsylvania, United States
• Johnston, Rhode Island, United States
• Orangeburg, South Carolina, United States
• Jackson, Tennessee, United States
• Memphis, Tennessee, United States
• Austin, Texas, United States
• Corpus Christi, Texas, United States
• Houston, Texas, United States
• Mesquite, Texas, United States
• Waco, Texas, United States
• Beckley, West Virginia, United States
• Camberwell, Australia
• Clayton, Australia
• Hobart, Australia
• Maroochydore, Australia
• Victoria Park, Australia
• + 106 more on CT.gov